Supernus Pharmaceuticals Reports Officer Compensation & Board Changes

TL;DR

**Supernus Pharmaceuticals just filed an 8-K about executive compensation and board changes, but the juicy details are missing from this snippet.**

AI Summary

Supernus Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting events from February 22, 2024. The filing primarily concerns changes in compensatory arrangements for certain officers and the departure or election of directors or officers. The specific details of these changes, including names and dollar amounts, were not provided in the excerpt.

Why It Matters

Changes in executive compensation and board composition can signal shifts in company strategy, financial health, or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — The filing indicates changes in executive compensation and board structure, which can introduce uncertainty, but the lack of specific details prevents a full assessment of the impact.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• February 22, 2024 (date) — Date of earliest event reported
• February 28, 2024 (date) — Filing date
• Delaware (company) — State of incorporation
• 9715 Key West Ave Rockville MD 20850 (company) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq S
• $963,000 — f Executive Officer, was increased from $963,000 to $1,001,500. Mr. Khattar was awarded
• $1,001,500 — Officer, was increased from $963,000 to $1,001,500. Mr. Khattar was awarded a 2023 bonus o
• $830,588 — Mr. Khattar was awarded a 2023 bonus of $830,588 and was granted options to purchase 322
• $453,800 — f Financial Officer, was increased from $453,800 to $485,500. Mr. Dec was awarded a 2023
• $485,500 — Officer, was increased from $453,800 to $485,500. Mr. Dec was awarded a 2023 bonus of $2
• $210,558 — 00. Mr. Dec was awarded a 2023 bonus of $210,558, and was granted options to purchase 50
• $427,700 — Scientific Officer, was increased from $427,700 to $440,500. Dr. Bhatt was awarded a 20
• $440,500 — Officer, was increased from $427,700 to $440,500. Dr. Bhatt was awarded a 2023 bonus of
• $163,165 — . Dr. Bhatt was awarded a 2023 bonus of $163,165 and was granted options to purchase 20,
• $440,000 — ief Medical Officer, was increased from $440,000 to $466,400. Dr. Rubin was awarded a 20
• $466,400 — Officer, was increased from $440,000 to $466,400. Dr. Rubin was awarded a 2023 bonus of
• $184,448 — . Dr. Rubin was awarded a 2023 bonus of $184,448 and was granted options to purchase 25,
• $356,700 — Regulatory Affairs, was increased from $356,700 to $367,400. Ms. Martin was awarded a 2
• $367,400 — Affairs, was increased from $356,700 to $367,400. Ms. Martin was awarded a 2023 bonus of

Filing Documents

• tm247469d1_8k.htm (8-K) — 33KB
• 0001104659-24-028783.txt ( ) — 202KB
• supn-20240222.xsd (EX-101.SCH) — 3KB
• supn-20240222_lab.xml (EX-101.LAB) — 33KB
• supn-20240222_pre.xml (EX-101.PRE) — 22KB
• tm247469d1_8k_htm.xml (XML) — 3KB

02. Departure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Modification of Compensatory Arrangements with Executive Officers On February 22, 2024, the Compensation Committee (the "Committee") of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") recommended, and the Board of Directors (the "Board") approved, modifications of the compensation of the Company's executive officers, as follows: The annual base salary of Jack A. Khattar, the Company's President and Chief Executive Officer, was increased from $963,000 to $1,001,500. Mr. Khattar was awarded a 2023 bonus of $830,588 and was granted options to purchase 322,000 shares of common stock and 193,200 performance share units (PSUs), which will vest depending upon the level of achievement of specified performance goals. In addition, Mr. Khattar's bonus target for 2024 is unchanged from 2023 and is 75% of his base salary. The annual base salary of Timothy C. Dec, the Company's Senior Vice President and Chief Financial Officer, was increased from $453,800 to $485,500. Mr. Dec was awarded a 2023 bonus of $210,558, and was granted options to purchase 50,000 shares of common stock, 12,000 restricted stock units (RSUs), and 12,000 PSUs, which will vest depending upon the level of achievement of specified performance goals. In addition, Mr. Dec's bonus target for 2024 is unchanged from 2023 and is 45% of his base salary. The annual base salary of Padmanabh P. Bhatt, Ph.D., the Company's Senior Vice President, Intellectual Property and Chief Scientific Officer, was increased from $427,700 to $440,500. Dr. Bhatt was awarded a 2023 bonus of $163,165 and was granted options to purchase 20,000 shares of common stock, 5,000 RSUs and 5,000 PSUs, which will vest depending upon the level of achievement of specified performance goals. Dr. Bhatt's bonus target for 2024 is unchanged from 2023 and is 35% of his base sal

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 10.1 - Form of Non-Statutory Time-Based Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.40 to the Form 10-K filed on February 27, 2024, File No. 001-35518). Exhibit 10.2 - Form of Restricted Stock Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to the Form 10-K filed on February 27, 2024, File No. 001-35518). Exhibit 10.3 - Form of Performance Share Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.44 to the Form 10-K filed on February 27, 2024, File No. 001-35518). Exhibit 104 - The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 28, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 4